Henry Kranzler, MD
Additional Information & Contact: Dept. of Psychiatry
Henry R. Kranzler, M.D. is Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine. His research focuses on the genetics and pharmacological treatment of substance dependence, with a particular emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health. He has authored or co-authored more than 600 journal articles, book chapters, and books, is a member of the editorial board of three peer-review journals, and is the Editor of Alcoholism: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach.
Grants & Funding
- Co-Principal Investigator on Million Veterans Program grant I01 BX003341 01: Genetic Vulnerability for Sustained Multi-Substance Use in MVP.
- Co-Principal Investigator on National Institute on Drug Abuse grant P30 DA046345: Penn PET Addiction Center of Excellence (Penn PACE)
Crist RC, Vickers-Smith R, Kember RL, Rentsch CT, Xu H, Edelman EJ, Hartwell EE, Kampman KM, Kranzler HR. Analysis of genetic and clinical factors associated with buprenorphine response. Drug and Alcohol Dependence. 227:109013, 2021.
Dao C, Zhou H, Small A, Gordon KS, Li B, Kember RL, Ye Y, Gelernter J, Xu K, Kranzler HR,* Zhao H,* Justice AC.* The impact of removing former drinkers from genome-wide association studies of AUDIT-C. Addiction. 116: 3044-3054, 2021. *Co-senior authors
Hartwell E, Merikangas A, Verma S, Ritchie M, Kranzler HR,* Kember RL.* Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals. Addiction Biology, in press. *Co-senior authors. 2021 Oct 5;e13099. doi: 10.1111/adb.13099. Online ahead of print.
Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, Arias AJ, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 115:1426-1437, 2020.
Kember RL, Vickers-Smith R, Zhou H, Xu H, Dao C, Justice AC, Gelernter J, Vujkovic M, Kranzler HR. Genetic underpinnings of the transition from alcohol consumption to alcohol use disorder: shared and unique genetic architectures in a cross-ancestry sample, medRxiv 2021.09.08.21263302; doi: https://doi.org/10.1101/2021.09.08.21263302
Knox J, Hasin DS, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry, 6:1054-1067, 2019.
Kranzler HR, Morris PE, Pond T, Crist RC, Kampman KM, Hartwell EE, Lynch KG. Prospective pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology. 46:1407-1413, 2021.
Kranzler HR, Washio Y, Zindel LR, Lynch KG, Hand D, Tyndale RF, Oncken C, Schnoll R. Pregnant smokers receiving opioid agonist therapy have an elevated nicotine metabolite ratio: A replication study. Nicotine & Tobacco Research. 10:1923-1927, 2020.
Kranzler HR, Zhou H, Kember RL, Smith RV, Justice AC, Damrauer S, Tsao PS, Klarin D, Rader DJ, Regeneron Genetics Center Research Team, Cheng Z, Tate JP, Becker WC, Concato J, Xu K, Polimanti R, Zhao H, Gelernter J on behalf of the VA Million Veteran Program. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications, 10:1499, 2019.
Wetherill RR, Spilka N, Jagannathan K, Morris P, Romer D, Pond T, Lynch KG, Kranzler HR. Topiramate alters neural responses to alcohol cues and heavy drinking among treatment-seeking individuals with alcohol use disorder. Neuropsychopharmacology. 46:1414-1420, 2021.
Witkiewitz K, Roos CR, Mann K, Kranzler HR. Advancing precision medicine for alcohol use disorder: A replication and extension of positive naltrexone response among reward drinkers. Alcoholism: Clinical and Experimental Research, 43:2395-2405, 2019
Xu K, Li B, McGinnis KA, Vickers-Smith R, Dao C, Sun N, Kember RL, Zhou H, Becker WC, Gelernter J, Kranzler HR, Zhao H, Justice AC; VA Million Veteran Program. Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. Nature Communications. 2020;11(1):5302.
Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, Tate JP, Dao C, Xu K, Polimanti R, Farrer LA, Justice AC, Kranzler HR, Gelernter J, Veterans Affairs Million Veteran Program. Association of OPRM1 functional coding variant with opioid use disorder. A genome-wide association study. JAMA Psychiatry, 77:1072-80, 2020.
Back to Top